Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Twist Bioscience Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Twist Bioscience Corp trades at $144 (market cap $9.82B). The key difference: Twist Bioscience Corp is far larger — about 10× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is more actively traded (2,742,564 versus 2,115,226). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| MRVI | TWST | |
|---|---|---|
Market Cap | $977.37M | $9.82B |
Volume | 2,742,564 | 2,115,226 |
Sector | Health | Health |
52-Week High | $9.00 | $205.00 |
52-Week Low | $2.83 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $1.08B | $9.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Twist Bioscience (TWST) trades at $151.33, down 0.35% on the day, with a bullish technical signal but negative profitability. Revenue growth is strong, increasing from $204M in 2022 to $377M in 2025, yet net losses persist. Recent news highlights a partnership with Eli Lilly's TuneLab AI platform, boosting investor optimism. The stock is near its consensus price target of $153.70, with institutional buying noted in Q2 2026.
Outlook remains speculative; growth prospects from AI-driven drug discovery are promising, but profitability challenges and cash burn pose significant risks. Analyst consensus is bullish (73% buy ratings), yet high valuation multiples and consistent earnings misses warrant caution for investors seeking near-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
